Berenberg raises target price on Convatec
Analysts at Berenberg raised their target price on medical device firm from 310.0p to 335.0p on Friday as it pointed to "good momentum" ahead of the company's interim results.
Berenberg noted that Convatec's shares had "a strong first half", up 32% year-to-date, and have benefited from continued progress across all of its segments, as well as delays to the implementation of local coverage determinations in wound care.
However, the German bank noted that even with the re-rating in the shares, Convatec trades on an "undemanding" 12.0x FY26 enterprise value/underling earnings ratio, despite mid-teens earnings growth estimated for 2025-27.
"Looking ahead, the company's trading update on 22 May suggests momentum in the business is strong ahead of H1 results on 29 July," said Berenberg. "As a result, we could see further upside to earnings expectations as we move through the year."
Berenberg also reiterated its 'buy' rating on the stock.
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.